Takeshi Yura joins AMRI in Singapore

Previously at Dishman Japan

Takeshi Yura has joined Albany Molecular Research Inc (AMRI) as assistant director, medicinal chemistry, reporting to managing director Raymond Yeung at the company’s drug discovery services operations in Singapore.

Yura brings more than 22 years of scientific and leadership experience in discovery chemistry, project management and business development to the company. Most recently, he was a director at Dishman Japan, responsible for sales and all business development activities for contract manufacturing services. Before that, he was discovery chemistry research head at Pfizer Japan, dedicated primarily to pain and gastrointestinal drug discovery. Prior to Pfizer, Yura was section head, medicinal chemistry at Bayer Yakuhin, focused on urology and asthma. He has held additional scientific roles at both Ciba Geigy Japan and Tanabe Seiyaku (now Mitsubishi Tanabe Pharma).

‘The addition of Dr Yura expands further our ability to provide integrated discovery services to our growing base of customers in Japan, throughout Asia and around the globe,’ said Yeung.

You may also like

Training & Education

Curia and Carterra partner on biologics symposium to further biotechnology research

The companies will run the high-throughput biologics symposium with a focus on the development of enhanced mouse systems for antibody generation and high-throughput single B cell screening
Research & Development

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA)
Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Manufacturing

Curia reveals continuous-flow collaboration with Corning

Continuous flow chemistry is critical for the development and manufacture of pharmaceutical intermediates and APIs
Research & Development

AMRI manufactures lipid excipients for Pfizer-BioNTech COVID-19 vaccine

AMRI has been providing development, scale-up and manufacturing services at a number of its global R&D and production sites for several months
Manufacturing

ViralClear partners with CDMO on potential COVID-19 treatment Merimepodib

ViralClear Pharmaceuticals has partnered with Albany Molecular Research Inc (AMRI) on the manufacture of Merimepodib API either as a stand-alone treatment or in combination with other antiviral agents or immune modulator
Manufacturing

AMRI to acquire Euticals

Strategic transaction expands API development and manufacturing business
Subscribe now